194156-54-2

Basic information

• Product Name: Carbamic acid, (2-methoxy-1-methylethyl)-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, (2-methoxy-1-methylethyl)-, 1,1-dimethylethyl ester (9CI);N-tert-Butyloxycarbonyl DL-Alaninol Methyl Ether;(2-Methoxy-1-Methylethyl)-carbaMic Acid 1,1-DiMethylethyl Ester;tert-Butyl 2-methoxy-1-methylethylcarbamate
• CAS NO: 194156-54-2
• Molecular Formula: C9H19NO3
• Molecular Weight: 189.25206
• Product Categories: N-BOC;Intermediates
• Mol File: 194156-54-2.mol

Chemical Properties

• Boiling Point: 255.8±23.0 °C(Predicted)
• Appearance: /
• Density: 0.964±0.06 g/cm3(Predicted)
• Solubility: Chloroform
• PKA: 12.11±0.46(Predicted)
• CAS DataBase Reference: Carbamic acid, (2-methoxy-1-methylethyl)-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (2-methoxy-1-methylethyl)-, 1,1-dimethylethyl ester (9CI)(194156-54-2)
• EPA Substance Registry System: Carbamic acid, (2-methoxy-1-methylethyl)-, 1,1-dimethylethyl ester (9CI)(194156-54-2)

Safety Data

• Hazardous Substances Data: 194156-54-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Carbamic acid, (2-methoxy-1-methylethyl)-, 1,1-dimethylethyl ester (9CI) is used as an intermediate in the synthesis of heterocyclic compounds, which are essential in the development of integrase inhibiting antiviral agents. These agents play a crucial role in the treatment and prevention of viral infections, particularly in the context of HIV and other retroviruses.
Used in Chemical Synthesis:
In the field of chemical synthesis, Carbamic acid, (2-methoxy-1-methylethyl)-, 1,1-dimethylethyl ester (9CI) serves as a valuable building block for the creation of various complex organic molecules. Its unique structure allows for further functionalization and modification, making it a useful component in the synthesis of a wide range of compounds with diverse applications.
Used in Research and Development:
Due to its unique chemical properties, Carbamic acid, (2-methoxy-1-methylethyl)-, 1,1-dimethylethyl ester (9CI) is also utilized in research and development for the exploration of new chemical reactions, mechanisms, and potential applications. Its versatility as a synthetic intermediate and its compatibility with various reaction conditions make it an attractive candidate for further investigation and development in the scientific community.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 37143-54-7 methoxyisopropylamine 
• 147252-84-4 tert-butyl (1-hydroxypropan-2-yl)carbamate 
• 74-88-4 methyl iodide 
• 79069-13-9 (R)-2-tertbutoxycarbonylamino-1-propanol 
• 79069-13-9 (S)-2-t-butoxycarbonylaminopropan-1-ol 

Downstream Products

• 677743-83-8 1-methoxypropan-2-amine hydrochloride 
• 626220-76-6 (2R)-(-)1-methoxypropan-2-amine hydrochloride 

Relevant articles and documents

SUBSTITUTED BENZIMIDAZOLES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS

This application relates to substituted benzimidazoles of formula (I), compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted benzimidazoles and to their use as bromodomain inhibitors. The present application also relates to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasm, including tumors and/or cancers.

PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES

An object is to provide a novel compound which has a glycogen synthase activation ability, but activates a receptor PPAR to a low degree and is highly safe. Provided is a compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof: wherein Ar1 represents any one of the following rings (II) and (III): wherein R2 represents an alkyl group, and R3 represents a hydrogen atom or an alkyl group, and R1 represents any one of the following substituents (IV) and (V):

TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted tetrazolyl, R2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R3, R4, R5 and R6 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X3 and/or a P2X2/3 receptor antagonist and methods of making the compounds.

THIAZOLE AND OXAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is a group of formula A or formula B, and X, R2, R3, R4, R5, R6, Ra and Rb are as defined herein. Also provided are methods of using the compounds for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist and methods of making the subject compounds.

OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS

Compounds of the formula 1: or a pharmaceutically acceptable salt thereof, wherein, X, Y, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.

INDOLE, INDAZOLE AND BENZIMIDAZOLE ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, X, Y, Z, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.

BIPHENYL AND PHENYL-PYRIDINE AMIDES AS P2X3 AND P2X2/3 ANTAGONISTS

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted phenyl or optionally substituted pyridinyl, and R2, R3, R4, R5, R6, R7, R8 and R9 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.

THIADIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted thiadiazolyl, and R2, R3, R4, R5, R6, R7 and R8 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.

Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted tetrazolyl, R2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R3, R4, R5, R6 R7 and R8 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X3 and/or a P2X2/3 receptor antagonist and methods of making the compounds.

Imidazole-substituted arylamides as P2X3 and P2X2/3 antagonists

Compounds of the formula I: wherein R1 is optionally substituted imidazolyl, and R2, R3, R4, R5, R6, R7 and R8 are as defined herein. Also provided are methods of using the compounds for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist and methods of making the subject compounds.